The lack of a systemic inflammatory response syndrome supports the safety of pancreatic electrolysis: experimental studies.
BACKGROUND
Per-ductal pancreatic electrolysis is a new minimally invasive ablation treatment. Possible applications include tumor debulking and treatment of chronic pancreatitis. Both solid organ ablation and pancreatitis are associated with the risk of an overwhelming systemic inflammatory response syndrome (SIRS) and multiorgan failure. TNF-alpha and IL1-beta are important cytokine mediators of this response. The aim of this study was to measure the circulating levels of IL1-beta and TNF-alpha following pancreatic electrolytic ablation as a marker of the risk of SIRS complicating per-ductal pancreatic electrolysis.


METHODS
Serum TNF-alpha and IL1-beta were measured in six treatment and six control pigs before and after laparotomy and pancreatic electrolytic ablation via a per-ductal approach.


RESULTS
There was no significant rise in serum TNF-alpha and IL1-beta in association with per-ductal pancreatic electrolysis.


CONCLUSIONS
This study supports the evidence that per-ductal electrolysis is a safe procedure with potential for palliative treatment of pancreatic cancers.
Teague
Benjamin D
BD
University of Adelaide Department of Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Morrison
Charles P
CP
Court
Fiona G
FG
Nguyen
Trung
T
Wemyss-Holden
Simon A
SA
Dennison
Ashley R
AR
Maddern
Guy J
GJ
D000681:Amylases / Q000097:blood; D000818:Animals; D002097:C-Reactive Protein / Q000378:metabolism; D004572:Electrolysis; D005260:Female; D007375:Interleukin-1 / Q000097:blood; D010179:Pancreas; D012307:Risk Factors; D013552:Swine; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology*; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D000681:Amylases